• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Monomeric M2e antigen in VesiVax? liposomes stimulates protection against type A strains of influenza comparable to liposomes with multimeric forms of

tetano

Editor, Senior Moderator
Liposome Res. 2017 Sep 18:1-31. doi: 10.1080/08982104.2017.1381708. [Epub ahead of print] [h=1]Monomeric M2e antigen in VesiVax? liposomes stimulates protection against type A strains of influenza comparable to liposomes with multimeric forms of M2e.[/h] Adler-Moore JP[SUP]1[/SUP], Ernst W[SUP]2[/SUP], Kim H[SUP]1[/SUP], Ward N[SUP]1[/SUP], Chiang SM[SUP]1[/SUP], Do T[SUP]2[/SUP], Fujii G[SUP]2[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Given the interest in the ectodomain of the matrix 2 (M2e) channel protein as a target for development of a universal influenza vaccine, we examined the role of the antigen configuration of M2e in generating a protective immune response. A series of M2e mutations and a truncated M2e segment were prepared as a means of controlling the formation of monomer, dimer, and higher order multimeric forms of M2e. Each of these M2e peptides was incorporated into a liposome-based vaccine technology platform previously shown to stimulate a protective response to influenza A infection using M2e as a mixture of monomers, dimers and multimers (L-M2e1-HD/MPL). Our results using these modified forms of M2e produced 90%-100% survival following lethal challenge with H1N1 (A/PR/8/34) in both inbred BALB/c and outbred Swiss Webster mice vaccinated with a truncated monomeric form of the M2 protein, M2e[SUB]1-15[/SUB] in liposomes. These observations show that a tetrameric configuration is not required to elicit significant protection when the M2e antigen is formulated in immunogenic liposomes and further, that the first 15 amino acids of M2e likely play a primary role in providing the protective immune response.


[h=4]KEYWORDS:[/h] influenza M2e; liposomes; vaccination

PMID: 28922045 DOI: 10.1080/08982104.2017.1381708
 
Back
Top Bottom